Tribune Therapeutics

Investment area

Seed Investments



Date of investment

May 2021

Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

Visit site


Jørgen Søberg Petersen

Senior Partner

Department: Seed Investments

After 9 years in clinical and academic medicine in Denmark and in the United States, Jørgen spent 18 years in R&D Executive positions in Denmark, Switzerland, United States, France and Germany. Jørgen co-founded and built the Nasdaq-listed biotech company Zealand Pharma (ZEAL.CO), held senior leadership at Lundbeck and Novo Nordisk, and as SVP at Merck he established the Immunology franchise. He has industrial R&D experience across multiple therapeutic areas, including CNS, cardiovascular disease, diabetes, oncology and autoimmune disease, and has been involved in a number of major pharmaceutical licensing deals and alliances. Jørgen serves on the board of Acesion Pharma, Engimmune Therapeutics, Breye Therapeutics, Hemab Therapeutics, and Tribune Therapeutics.

Jørgen holds MD, PhD, and DMSc degrees from the University of Copenhagen and an MBA degree from the Technical University of Denmark.


João Ribas


Department: Seed Investments

João Ribas joined Seed Investments in 2018, focusing on early-stage investments and venture creation. He currently holds several board positions and has led investments in companies like Asgard Therapeutics, Tribune Therapeutics, and Orbis Medicines. João often combines his investment role with interim operational responsibilities in portfolio companies.

Prior to Novo Holdings, he was a Fellow at M Ventures (corporate VC of Merck KGaA), involved in the entire investment process including deal sourcing, investment selection, and due diligence. Before this, João founded new ventures in the U.S. and Europe, earning several entrepreneurial awards. During his Ph.D., he was part of MIT Hacking Medicine and led a non-profit organization in the U.S.

João earned his Ph.D. from the University of Coimbra, conducting research at Harvard Medical School and Brigham and Women’s Hospital. He regularly creates content on biotech innovation, venture creation, and entrepreneurship.